NMPA grants marketing approval for Mabpharm’s infliximab ‘biobetter’

Jul 20, 2021

Sorrento announced that China’s NMPA has granted marketing approval for Mabpharm’s infliximab ‘biobetter’. Sorrento holds exclusive commercial rights to the product outside of China and disclosed that it plans to file a BLA in the EU and US in 2021.

Print Page Mail Article